Key result
Anticoagulation in cancer-associated VTE requires balancing risks of recurrence and bleeding.
Observational analysis explores recurrence risks and bleeding concerns in cancer patients undergoing anticoagulation.
Journal Article Anticoagulation for cancer-associated venous thromboembolism: navigating between risks of recurrence and bleeding Get access Sabine Eichinger, Sabine Eichinger Division of Hematology and Hemostasis, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18–20, Vienna 1090, AustriaKarl Landsteiner Institute of Thrombosis Research, Vienna, Austria Corresponding author. Email: [email protected] https://orcid.org/0000-0003-1135-4878 Search for other works by this author on: Oxford Academic PubMed Google Scholar Paul A Kyrle Paul A Kyrle Division of Hematology and Hemostasis, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18–20, Vienna 1090, AustriaKarl Landsteiner Institute of Thrombosis Research, Vienna, Austria Search for other works by this author on: Oxford Academic PubMed Google Scholar European Heart Journal, ehaf585, https://doi.org/10.1093/eurheartj/ehaf585 Published: 05 September 2025
No takes yet. Share an insight, caveat, or question.
Eichinger et al. (2025) conducted an editorial in Cancer-associated venous thromboembolism. Anticoagulation was evaluated. This article discusses anticoagulation strategies for cancer-associated venous thromboembolism, focusing on balancing the risks of recurrence and bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: